EUVIMEDEUVIMED entdecken
Crossref

Legal analysis assails FDA's lowering of standards for drug approval

The Brown University Psychopharmacology Update · 2026-04 · 37 (4) · 1-5

DOI: 10.1002/pu.31424 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Brown University Psychopharmacology Update, online erschienen am 14.03.2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Food and Drug Administration's (FDA's) announcement last fall that it intends to approve a new indication for the folic acid derivative leucovorin signals a dangerous departure from long‐held evidentiary standards for drug approval, a group of legal and bioethics experts suggested in a published commentary. The authors wrote that the FDA has moved to approve leucovorin for some patients with autism despite having no evidence of benefit from any randomized controlled trial. Their viewpoint article was published online Dec. 22, 2025 in JAMA .

Zitieren

APA

(2026). Legal analysis assails FDA's lowering of standards for drug approval. The Brown University Psychopharmacology Update, 37(4), 1-5. https://doi.org/10.1002/pu.31424

Vancouver

Legal analysis assails FDA's lowering of standards for drug approval. The Brown University Psychopharmacology Update. 2026;37(4):1-5. doi:10.1002/pu.31424

BibTeX
@article{euvimed2026,
  title = {Legal analysis assails FDA's lowering of standards for drug approval},
  journal = {The Brown University Psychopharmacology Update},
  year = {2026},
  volume = {37},
  number = {4},
  pages = {1--5},
  doi = {10.1002/pu.31424}
}
Kostenlos starten →